Mycophenolate is already a generic name of the original drug Cellcept. The active ingredient is mycophenolate mofetil.
Researchers have discovered that mycophenolate mofetil is an immunosuppressant drug commonly used to prevent rejection in transplant patients by inhibiting the proliferation of T and B lymphocytes. It has also been found to be effective in treating autoimmune diseases such as lupus nephritis and inflammatory bowel disease. Additionally, studies have shown that mycophenolate mofetil may have potential in treating certain types of cancers due to its anti-proliferative properties.
There has been a recent, welcome development in renal sparing drugs, such as mycophenolate mofetil
cyclosporine, prednisone, azathioprine, tacrolimus or FK506, mycophenolate mofetil, sirolimus, and OKT3, as well as ATGAM and Thymoglobulin.
cyclosporine, prednisone, azathioprine, tacrolimus or FK506, mycophenolate mofetil, sirolimus, and OKT3, as well as ATGAM and Thymoglobulin.
yes it is, my mom has had lupus fpr over 8 years and it has she just began her treatments about 6 months ago. They are working alot! : )
Second-line immunosuppressive agents refer to medications that are used when initial treatments for a medical condition have failed or when more aggressive therapy is needed. These medications may include drugs such as mycophenolate mofetil, azathioprine, and cyclophosphamide, and are often used to help manage autoimmune diseases or prevent organ rejection after transplantation.
Mycophenolate is an immunosuppresive agent. It is used to lower the body's natural immunity and is used in patients who receive organ transplants.
Medications vary widely based on what organs are affected by the autoimmune activity. Antimalarials, prednisone and NSAIDS are used most commonly. Chemotherapies like methotrexate and cytoxan are sometimes used. Cellcept (mycophenolate mofetil) which is used to prevent organ transplant rejection is now being used for many lupus patients. New biologics are being developed which interrupt the autoimmune activity at the level of B cells. Benlysta is on its way to FDA approval and will be the first new medication developed and approved specifically for lupus since November 20, 1958.
Lupus is an autoimmune disease that can affect any part of the body. Lupus affects each patient differently. Because of that, a variety of medications are used to manage lupus, many of them "off label" or not approved by the FDA for treatment of lupus. The four drugs approved by the FDA are aspirin, hydroxychloroquine, prednisone and Benlysta (belimumab) which is give by IV infusion. Subcutaneous clinical trials are now underway for Benlysta. Off label drugs include methotrexate, azathioprine, cytoxan, mycophenolate mofetil, rituximab and a variety of non steroidal anti inflammator medications.
"dosage" is a noun.
The dosage of a Watson 3203 and a Watson 349 will depend on the doctors dosage. Each patient will be prescribed a different dosage.